JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation-Reference-Cited by-同舟云学术

JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

Published:2012-07-24 Issue:10 Volume:103 Page:1795-1802
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Harada Daijiro¹,Takigawa Nagio²,Ochi Nobuaki,Ninomiya Takashi¹,Yasugi Masayuki¹,Kubo Toshio¹,Takeda Hiromasa¹,Ichihara Eiki³,Ohashi Kadoaki¹,Takata Saburo¹,Tanimoto Mitsune¹,Kiura Katsuyuki³

Affiliation:

1. Department of Hematology, Oncology, and Respiratory Medicine; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; Okayama; Japan

2. Department of General Internal Medicine 4; Kawasaki Medical School; Okayama; Japan

3. Department of Respiratory Medicine; Okayama University Hospital; Okayama; Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2012.02363.x/fullpdf

Reference48 articles.

1. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths;Siegel;CA Cancer J Clin,2011

2. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours;Goldstraw;J Thorac Oncol,2007

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004